Reusser P, Fisher LD, Buckner CD, Thomas ED, Meyers JD. Cytomegalovirus infection after autologous bone marrow transplantation: occurrence of cytomegalovirus disease and effect on engraftment. Blood. 1990;75(9):1888–94.

Article  CAS  PubMed  Google Scholar 

Takenaka K, Gondo H, Tanimoto K, Nagafuji K, Fujisaki T, Mizuno S, et al. Increased incidence of cytomegalovirus (CMV) infection and CMV-associated disease after allogeneic bone marrow transplantation from unrelated donors The Fukuoka Bone Marrow Transplantation Group. Bone Marrow Transplant. 1997;19(3):241–8.

Article  CAS  PubMed  Google Scholar 

Jinnouchi F, Mori Y, Yoshimoto G, Yamauchi T, Nunomura T, Yurino A, et al. Incidence of refractory cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation. Int J Hematol. 2022;115(1):96–106.

Article  CAS  PubMed  Google Scholar 

Einsele H, Ehninger G, Hebart H, Wittkowski KM, Schuler U, Jahn G, et al. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood. 1995;86(7):2815–20.

Article  CAS  PubMed  Google Scholar 

Boeckh M, Gooley TA, Myerson D, Cunningham T, Schoch G, Bowden RA. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood. 1996;88(10):4063–71.

Article  CAS  PubMed  Google Scholar 

Marty FM, Ljungman P, Chemaly RF, Maertens J, Dadwal SS, Duarte RF, et al. Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. N Engl J Med. 2017;377(25):2433–44.

Article  CAS  PubMed  Google Scholar 

Akahoshi Y, Kimura SI, Inamoto Y, Seo S, Muranushi H, Shimizu H, et al. Effect of cytomegalovirus reactivation with or without acute graft-versus-host disease on the risk of nonrelapse mortality. Clin Infect Dis. 2021;73(3):e620–8.

Article  PubMed  Google Scholar 

Ljungman P, Oberg G, Aschan J, Ehrnst A, Lönnqvist B, Pauksen K, et al. Foscarnet for pre-emptive therapy of CMV infection detected by a leukocyte-based nested PCR in allogeneic bone marrow transplant patients. Bone Marrow Transplant. 1996;18(3):565–8.

CAS  PubMed  Google Scholar 

Littler E, Stuart AD, Chee MS. Human cytomegalovirus UL97 open reading frame encodes a protein that phosphorylates the antiviral nucleoside analogue ganciclovir. Nature. 1992;358(6382):160–2.

Article  CAS  PubMed  Google Scholar 

Crumpacker CS. Ganciclovir. N Engl J Med. 1996;335(10):721–9.

Article  CAS  PubMed  Google Scholar 

Moretti S, Zikos P, Van Lint MT, Tedone E, Occhini D, Gualandi F, et al. Forscarnet vs ganciclovir for cytomegalovirus (CMV) antigenemia after allogeneic hemopoietic stem cell transplantation (HSCT): a randomised study. Bone Marrow Transplant. 1998;22(2):175–80.

Article  CAS  PubMed  Google Scholar 

Reusser P, Einsele H, Lee J, Volin L, Rovira M, Engelhard D, et al. Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood. 2002;99(4):1159–64.

Article  CAS  PubMed  Google Scholar 

Miyao K, Terakura S, Ozawa Y, Sawa M, Kohno A, Kasahara S, et al. Comparison of transplantation outcomes after foscarnet and ganciclovir administration as first-line anti-cytomegalovirus preemptive therapy. Transplant Cell Ther. 2021;27(4):3421.e1-e10.

Google Scholar 

Atsuta Y, Suzuki R, Yoshimi A, Gondo H, Tanaka J, Hiraoka A, et al. Unification of hematopoietic stem cell transplantation registries in Japan and establishment of the TRUMP System. Int J Hematol. 2007;86(3):269–74.

Article  PubMed  Google Scholar 

Mehta RS, Holtan SG, Wang T, Hemmer MT, Spellman SR, Arora M, et al. Composite GRFS and CRFS outcomes after adult alternative donor HCT. J Clin Oncol. 2020;38(18):2062–76.

Article  PubMed  PubMed Central  Google Scholar 

Pasquini MC, Logan B, Jones RJ, Alousi AM, Appelbaum FR, Bolaños-Meade J, et al. Blood and marrow transplant clinical trials network report on the development of novel endpoints and selection of promising approaches for graft-versus-host disease prevention trials. Biol Blood Marrow Transplant. 2018;24(6):1274–80.

Article  PubMed  PubMed Central  Google Scholar 

Lee SJ, Vogelsang G, Flowers ME. Chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2003;9(4):215–33.

Article  CAS  PubMed  Google Scholar 

Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995;15(6):825–8.

CAS  PubMed  Google Scholar 

Giralt S, Ballen K, Rizzo D, Bacigalupo A, Horowitz M, Pasquini M, et al. Reduced-intensity conditioning regimen workshop: defining the dose spectrum. report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transplant. 2009;15(3):367–9.

Article  PubMed  PubMed Central  Google Scholar 

Popli R, Sahaf B, Nakasone H, Lee JY, Miklos DB. Clinical impact of H-Y alloimmunity. Immunol Res. 2014;58(2–3):249–58.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Toubai T, Tawara I, Sun Y, Liu C, Nieves E, Evers R, et al. Induction of acute GVHD by sex-mismatched H-Y antigens in the absence of functional radiosensitive host hematopoietic-derived antigen-presenting cells. Blood. 2012;119(16):3844–53.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Randolph SS, Gooley TA, Warren EH, Appelbaum FR, Riddell SR. Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants. Blood. 2004;103(1):347–52.

Article  CAS  PubMed  Google Scholar 

Gallardo D, Pérez-García A, de la Cámara R, Iriondo A, Jiménez-Velasco A, Torres A, et al. Clinical outcome after sex-mismatched allogeneic stem cell transplantation from human lymphocyte antigen-identical sibling donors: influence of stem cell source. Leukemia. 2006;20(8):1461–4.

Article  CAS  PubMed  Google Scholar 

Nannya Y, Kataoka K, Hangaishi A, Imai Y, Takahashi T, Kurokawa M. The negative impact of female donor/male recipient combination in allogeneic hematopoietic stem cell transplantation depends on disease risk. Transpl Int. 2011;24(5):469–76.

Article  PubMed  Google Scholar 

Konuma T, Kato S, Ooi J, Oiwa-Monna M, Ebihara Y, Mochizuki S, et al. Impact of sex incompatibility on the outcome of single-unit cord blood transplantation for adult patients with hematological malignancies. Bone Marrow Transplant. 2014;49(5):634–9.

Article  CAS  PubMed  Google Scholar 

Loren AW, Bunin GR, Boudreau C, Champlin RE, Cnaan A, Horowitz MM, et al. Impact of donor and recipient sex and parity on outcomes of HLA-identical sibling allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2006;12(7):758–69.

Article  PubMed  Google Scholar 

Miyao K, Kuwatsuka Y, Murata M, Nagafuji K, Teshima T, Takeuchi Y, et al. Antithymocyte globulin potentially could overcome an adverse effect of acute graft-versus-host disease in matched-related peripheral blood stem cell transplantation. Transplant Cell Ther. 2022;28(3):1531.e1-e11.

Google Scholar 

Koyama D, Murata M, Hanajiri R, Akashi T, Okuno S, Kamoshita S, et al. Quantitative assessment of t cell clonotypes in human acute graft-versus-host disease tissues. Biol Blood Marrow Transplant. 2019;25(3):417–23.

Article  CAS  PubMed  Google Scholar 

Inamoto Y, Storer BE, Petersdorf EW, Nelson JL, Lee SJ, Carpenter PA, et al. Incidence, risk factors, and outcomes of sclerosis in patients with chronic graft-versus-host disease. Blood. 2013;121(25):5098–103.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nikoloudis A, Wagner H, Machherndl-Spandl S, Buxhofer-Ausch V, Strassl I, Stiefel O, et al. Relapse protection following early cytomegalovirus reactivation after hematopoietic stem cell transplantation is limited to HLA-C killer cell immunoglobulin-like receptor ligand homozygous recipients. Transplant Cell Ther. 2021;27(8):686.e1-e9.

Article  CAS  PubMed  Google Scholar 

Peric Z, Wilson J, Durakovic N, Ostojic A, Desnica L, Vranjes VR, et al. Early human cytomegalovirus reactivation is associated with lower incidence of relapse of myeloproliferative disorders after allogeneic hematopoietic stem cell transplantation. Bone Mar